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BACKGROUND
• Patients presenting with acute ischemic stroke in the 
emergency department often require management with 
antihypertensive agents
• According to the most recent update of the 2018 
AHA/AIS guidelines for early management of acute 
ischemic stroke, blood pressure should be maintained 
at < 180/105 mmHg for the first 24 hours following 
alteplase therapy
• There is limited data to support one antihypertensive 
lowering strategy over another. Given this there might 
be a difference when comparing IV bolus versus IV 
infusion medications. The rationale is that the 
treatment options expressed in the guidelines have 
different durations of action which might impact their 
blood pressure lowering capabilities
• Furthermore, the amount of nursing needed for titrating 
infusions or administering boluses may be an 
additional motivating factor to prefer one approach 
over another
OBJECTIVES
• The primary objective of this study is to investigate 
whether there is a difference between an IV bolus or 
IV infusion approach in achieving  Systolic Blood 
Pressure < 180/105 mmHg within 1 hour and 
maintaining blood pressure goal up to 4 hours post 
initial blood pressure medication administration
• The primary safety outcome of this trial is evidence of 
hemorrhage within 24 hours following TPA 
administration
METHODS
• Retrospective review study of approximately 200 patients
• Data will be extracted from the electronic medical record of patients 
admitted to Valley Hospital Medical Center between January 2015 and 
September 2020 who received one dose of tPA for the treatment of acute 
ischemic stroke
• Inclusion Criteria
• > 18 years of age
• Diagnosis of AIS requiring tPA administration
• Received either IV bolus or IV infusion of antihypertensive for BP control 
within 4 hours of tPA administration
• Have at least one recorded blood pressure within 4 hours after initial 
administration of antihypertensive agent
• Exclusion Criteria
• Contraindications to tPA
• Did not require antihypertensive agent for blood pressure control within 4 
hours of tPA administration




• Blood pressure on admission
• Heart rate on admission
• NIH stroke scale on admission
• External fill history of antiplatelets and/or anticoagulants
• History of previous stroke
• Diagnosis of hypertension
• Use of antihypertensives in the home medication list
DISCUSSION
• Chi-squared or Fisher’s exact test will be performed for 
analyze of achievement of target blood pressure and 
other categorical data
• Paired t-test or a Wilcoxin signed rank test will be 
performed to analyze continuous data
• Research findings may be incorporated to make 
improvements to hospital stroke protocols and provide 
education to healthcare providers 
• Chi-squared or Fisher’s exact test will be performed for 
analyze of achievement of target blood pressure and 
other categorical data
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